DOCSLIB.ORG

Locators in Italics Refer to Figures. AAM See Aggressive

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Locators in Italics Refer to Figures. AAM See Aggressive Cambridge University Press 978-1-107-56727-6 — Modern Soft Tissue Pathology 2nd Edition Index More Information Index Locators in italics refer to Figures. AAM see aggressive adenocarcinoma see also aggressive digital papillary appearance 896, 896 angiomyxoma carcinoma adenocarcinoma clinical features abdominal endometriosis 506–507 aggressive digital papillary 764–765, 765, 766 soft tissue 895 histopathology 507, 508 764–765, 765–766 aggressive fibromatosis see visceral sites 895–896 abdominal ependymoma keratins 65 desmoid fibromatosis cytology 1005, 1005–1006 711–713, 713 pancreatic 809 AIDS see HIV/AIDS differential diagnosis 737, 900 abdominal inflammatory pulmonary 792–793, 805, 806 AJCC staging system 5 electron microscopy 899, 899 myofibroblastic tumor adenofibroma 505 AKT/mTOR signaling pathway genetics 129, 900 (IMT) 289 adenomatoid tumor 777, 778 128, 136 histogenesis 899–900 epithelioid variant 290, 291 adenomatous polyposis coli gene inhibitors 133, 518 histopathology 896–898, abdominal wall desmoid tumor (APC) 137–138, 245–246 ALCL see anaplastic large cell 897–898 239–241 adenosarcoma 505 lymphoma immunohistochemistry abscesses 33–34 adipose tissue pathology see also alcohol fixation 8 898–899, 899 aCGH (array-CGH) 100–101, lipoblastoma; ALK/ALK (anaplastic lymphoma metastatic disease 1027 123, 143 lipodystrophy; kinase) American Joint Committee of acquired elastotic hemangioma lipogranuloma; lipoma; in ALCL 952–954 Cancer (AJCC) staging 575, 577 lipomatoses; liposarcoma as an IHC marker 70, 291 system 5 acquired progressive cytology 977–982 gene fusion 124, 127, 292, AML see angiomyolipoma lymphangioma (benign imaging 19–25 953–954 amplification of genes 98–99, lymphangioendothelioma) immunohistochemistry 46, 57, in inflammatory 101, 130–131, 611, 585–587 72 myofibroblastic tumor 875–876 histopathology 586, 586–587 adrenal gland 127, 291–292 amputation 1015 acquired tufted angioma cortical tumors in neuroblastoma 130–131, 877 amputation (traumatic) neuroma 566–567, 568 carcinoma 60, 815, 816 alkaptonuric ochronosis 913, 914 30, 639, 640 acral arteriovenous tumor myelolipoma 390, 391 allele-specific PCR (AS-PCR) 141 amyloid tumor (amyloidoma) (arteriovenous medullary tumors see alpha smooth muscle actin 50, 546 936–938, 937–938 hemangioma) 26, pheochromocytoma Alport syndrome 450 anaplastic large cell lymphoma 561–562, 562 adult fibrosarcoma 336, 351–352 ALT (atypical lipomatous tumor) (ALCL) acral myxoinflammatory cytology 984, 985 see well-differentiated noncutaneous (systemic) fibroblastic sarcoma spindle cells 352–353 liposarcoma 952–954, 953 352–356 adult granulosa cell tumor 505–506 altitude (and carotid body primary cutaneous 954 appearance 354 appearance 506 paraganglioma) 735 anaplastic lymphoma kinase see cytology 984, 985 histopathology 505–506, 506 alveolar rhabdomyosarcoma ALK/ALK differential diagnosis 354–355, immunohistochemistry 506, 507 (alveolar sarcoma) anaplastic rhabdomyosarcoma 984 adult myofibroma 267, 270–271 539–541 543–544, 544 histopathology 354, 355 adult rhabdomyoma 529,529–530 cytology 994, 994 anaplastic spindle cell pseudolipoblasts 356 adults with “pediatric” sarcomas genetics 129, 134–135, rhabdomyosarcoma 542 Reed–Sternberg-like cells 356 1031 539–541, 542, 878–879 ancient hematoma see organizing acroangiodermatitis (pseudo- AFH see angiomatoid fibrous histopathology 539, hematoma Kaposi’ssarcoma)580, 580 histiocytoma 540–541 ancient schwannoma 655, actins 49–50, 546 AFX see atypical fibroxanthoma leukemoid variant 540 989–990, 990 acute myeloid leukemia 954 age, and tumor type 19 imaging 539 aneuploidy 98–99 ACVR1 (activin-like receptor) aggressive angiomyxoma (AAM) immunohistochemistry 546, hyperdiploidy 548, 876–877 845 female 498–501 547 trisomy 237, 246, 294, 506, adamantinoma 770, 770 appearance 498, 499 mixed with embryonal form 544 921 adamantinoma-like Ewing histopathology 498–499, 500 alveolar soft part sarcoma aneurysmal bone cyst 104, sarcoma 99 male 498 (ASPS) 895–900 844–845 1036 © in this web service Cambridge University Press www.cambridge.org Cambridge University Press 978-1-107-56727-6 — Modern Soft Tissue Pathology 2nd Edition Index More Information Index aneurysmal fibrous histiocytoma cytology 1000–1001, 1002 in lymphedematous B-cell lymphoma 224–225, 224 differential diagnosis 517 extremities 4, 603–604 Burkitt lymphoma 949, 950 angioblastic meningioma genetics 517–518 in nerve sheath tumors 607, and crystal-storing histiocytosis (meningeal SFT) 324–325, histopathology 515–517, 515 659, 683 964–965, 965–966 331 epithelioid 517, 517 postradiation 603 diffuse large 947, 948 angioblastoma of Nakagawa lipomatous component 515, rare sites 607 extranodal marginal zone (acquired tufted 515–516 splenic 606 946–947, 947 angioma) 566–567, 568 smooth muscle component treatment 1018 follicular 945–946, 946 angioendothelioma see papillary 516–517, 516 angulated bodies 673 intravascular 948–949, 949 intralymphatic vascular component 516,516 anoctamin-1 484–485 lymphoblastic 947–948, 948 angioendothelioma immunohistochemistry 59, 59, anthracyclines see doxorubicin plasmablastic 949–950, 951 angioendotheliomatosis, reactive 60, 61, 517 Antoni A/Antoni B areas in bacillary angiomatosis 578–579 579–580 angiomyoma (angioleiomyoma) schwannoma 655 histopathology 578, 579 angiofibroma, cellular (vulvar) 446–447 aorticopulmonary Warthin–Starry stain of 496–497, 497–498 histopathology 446–447, paraganglioma 734 Bartonella 579 angiofibroma, giant cell 330, 331 448–449 APC (adenomatous polyposis BAF47 protein 74, 133–134 see angiofibroma, juvenile angiomyomatous hamartoma of coli) 137–138, 245–246 also INI1/INI1 nasopharyngeal 263–264, lymph node 444, 445 appearance see gross anatomy/ (SMARCB1) 263–265 angiomyxoma, aggressive morphology Baker (popliteal) cyst 17,31–32, 33 angiogenesis 553 female 498–501 appendiceal GISTs 481 BAP1/BAP1 (BRCA1-associated angiography 13, 29 appearance 498, 499 array-CGH (aCGH) 100–101, protein) 794 angiokeratoma 559–560, 561 histopathology 498–499, 500 123, 143 Bartonella infections angioleiomyoma 446–447 male 498 arsenic 4, 798 bacillary angiomatosis histopathology 446–447, angiomyxoma, superficial arteriovenous hemangioma 26, 578–579, 579 448–449 (cutaneous myxoma) 561–562, 562 verruga peruana 579 angiolipoma 388–390 306–310 arthritis see also pseudogout Warthin–Starry stain 579 histopathology 389, 389 clinical features 306–307, 309 gout 841, 903, 907, 909–910 basal cell keratins 67–68 cellular variant 389–390, 390 differential diagnosis osteoarthritis 905–906, 907 basal cell nevus syndrome (Gorlin infiltrative see intramuscular 307–308 rheumatoid 904–905, 906 syndrome) 529 hemangioma genetics 309–310 septic 903–904, 904 basement membrane proteins 72 angiolymphoid hyperplasia with histopathology 307, 308–309 AS see angiosarcoma BCL2 protein 70 eosinophilia see angiosarcoma (AS) 593, 601–611, asbestos 782–783 BCOR gene 124, 866–867 epithelioid hemangioma 1031 asbestos fibers 782 BCOR-CCNB3 fusion sarcoma angiomatoid fibrous appearance ferruginous bodies 782–783, 866–867, 866–867 histiocytoma (AFH) breast 605 783 Beckwith–Wiedemann 283–288 deep soft tissue 606 Askin’s tumor (chest wall Ewing syndrome 535, 856 appearance 284–285 lymphedematous arm 604 sarcoma) 856 see also Bednar tumor (pigmented histopathology 284–285, 286 scalp 603 Ewing sarcoma family of variant of DFSP) 342, 342 cysts 286 breast parenchyma 604–605 tumors benign fibrous histiocytoma hemorrhagic appearance cardiovascular 606–607 ASPS see alveolar soft part (BFH, dermatofibroma) 286–287 in children 606, 608 sarcoma 220–228 resembling lymph node cutaneous (face and scalp) ASPSCR1 (ASPL)-TFE3 gene appearance 220–221, 221, 224 metastasis 285 602–603 fusion 129, 900 clinical features 220 variations 287–288 cytology 995–997, 998 ATF1/ATF gene fusion 126, 287– cytology 987, 988 angiomatosis 562–564 of deep soft tissues 605, 608 288, 707–708 differential diagnosis 224–226, histopathology 563–564, 565 differential diagnosis 27, 605, atypical decubital fibroplasia 344–345, 987 imaging 27, 29 608–610, 996–997 (ischemic fasciitis) 195 genetics 228 angiomatosis, bacillary 578–579 etiology 3–4, 593 histopathology 195, 197 histopathology 221–222, 222–223 histopathology 578, 579 foreign-body-associated atypical fibrous histiocytoma aneurysmal variant 224, Warthin–Starry stain of 607–608 226–228, 227 224–225 Bartonella 579 genetics 611 atypical fibroxanthoma (AFX) atypical variant 227 angiomatous lesions see in germ cell tumors 607 364–367 cellular variant 225–226 angiomatosis; hepatic 3–4, 606 appearance 365 epithelioid variant 226 angiosarcoma; histopathology 608 histopathology 365–366, 366 lipidized variant 227 hemangioendothelioma; breast parenchyma 605 immunohistochemistry 366, 367 immunohistochemistry hemangioma; epithelioid 608, 609–610 atypical glomus tumor 626, 630 222–224, 225, 227, 223 hemangiopericytoma; hepatic 606 atypical lipomatous tumor (ALT) metastasis 221 lymphangioma lymphoid infiltration 609 see well-differentiated recurrence 220 angiomyofibroblastoma, vulvar poorly differentiated 610 liposarcoma variants 224 494–496, 495–496 radiation-induced 603, 604 atypical mesothelial hyperplasia aneurysmal 224–225, 224 angiomyofibroblastoma-like splenic 607 790 atypical 226–228, 227 tumors in men 496–497, well-differentiated 608 atypical tenosynovial giant cell cellular 225–226, 225 497 imaging 27 tumor 921–922, 922 epithelioid 225, 226 angiomyolipoma (AML) 513–518 immunohistochemistry 45, 66, atypical teratoid/rhabdoid tumor granular cell 228 appearance 514 610–611, 611 882, 885 lipidized 225–226, 227 1037 © in this web service
Load more

Recommended publications
  • Appendix 4 WHO Classification of Soft Tissue Tumours17
    S3.02 The histological type and subtype of the tumour must be documented wherever possible. CS3.02a Accepting the limitations of sampling and with the use of diagnostic common sense, tumour type should be assigned according to the WHO system 17, wherever possible. (See Appendix 4 for full list). CS3.02b If precise tumour typing is not possible, generic descriptions to describe the tumour may be useful (eg myxoid, pleomorphic, spindle cell, round cell etc), together with the growth pattern (eg fascicular, sheet-like, storiform etc). (See G3.01). CS3.02c If the reporting pathologist is unfamiliar or lacks confidence with the myriad possible diagnoses, then at this point a decision to send the case away without delay for an expert opinion would be the most sensible option. Referral to the pathologist at the nearest Regional Sarcoma Service would be appropriate in the first instance. Further International Pathology Review may then be obtained by the treating Regional Sarcoma Multidisciplinary Team if required. Adequate review will require submission of full clinical and imaging information as well as histological sections and paraffin block material. Appendix 4 WHO classification of soft tissue tumours17 ADIPOCYTIC TUMOURS Benign Lipoma 8850/0* Lipomatosis 8850/0 Lipomatosis of nerve 8850/0 Lipoblastoma / Lipoblastomatosis 8881/0 Angiolipoma 8861/0 Myolipoma 8890/0 Chondroid lipoma 8862/0 Extrarenal angiomyolipoma 8860/0 Extra-adrenal myelolipoma 8870/0 Spindle cell/ 8857/0 Pleomorphic lipoma 8854/0 Hibernoma 8880/0 Intermediate (locally
    [Show full text]
  • View Open Access Histological Variants of Cutaneous Kaposi Sarcoma Wayne Grayson1 and Liron Pantanowitz*2
    Diagnostic Pathology BioMed Central Review Open Access Histological variants of cutaneous Kaposi sarcoma Wayne Grayson1 and Liron Pantanowitz*2 Address: 1Histopathology Department, Ampath National Laboratory Support Services, Johannesburg, South Africa and 2Department of Pathology, Baystate Medical Center, Tufts University School of Medicine, Springfield, Massachusetts, USA Email: Wayne Grayson - [email protected]; Liron Pantanowitz* - [email protected] * Corresponding author Published: 25 July 2008 Received: 23 July 2008 Accepted: 25 July 2008 Diagnostic Pathology 2008, 3:31 doi:10.1186/1746-1596-3-31 This article is available from: http://www.diagnosticpathology.org/content/3/1/31 © 2008 Grayson and Pantanowitz; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract This review provides a comprehensive overview of the broad clinicopathologic spectrum of cutaneous Kaposi sarcoma (KS) lesions. Variants discussed include: usual KS lesions associated with disease progression (i.e. patch, plaque and nodular stage); morphologic subtypes alluded to in the older literature such as anaplastic and telangiectatic KS, as well as several lymphedematous variants; and numerous recently described variants including hyperkeratotic, keloidal, micronodular, pyogenic granuloma-like, ecchymotic, and intravascular KS. Involuting lesions as a result of treatment related regression are also presented. Introduction progression, (2) KS variants alluded to in the older litera- Kaposi sarcoma (KS) is a vascular lesion of low-grade ture, (3) more recently described KS variants, and (4) KS malignant potential that presents most frequently with lesions as a consequence of therapy.
    [Show full text]
  • The Role of Cytogenetics and Molecular Diagnostics in the Diagnosis of Soft-Tissue Tumors Julia a Bridge
    Modern Pathology (2014) 27, S80–S97 S80 & 2014 USCAP, Inc All rights reserved 0893-3952/14 $32.00 The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors Julia A Bridge Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA Soft-tissue sarcomas are rare, comprising o1% of all cancer diagnoses. Yet the diversity of histological subtypes is impressive with 4100 benign and malignant soft-tissue tumor entities defined. Not infrequently, these neoplasms exhibit overlapping clinicopathologic features posing significant challenges in rendering a definitive diagnosis and optimal therapy. Advances in cytogenetic and molecular science have led to the discovery of genetic events in soft- tissue tumors that have not only enriched our understanding of the underlying biology of these neoplasms but have also proven to be powerful diagnostic adjuncts and/or indicators of molecular targeted therapy. In particular, many soft-tissue tumors are characterized by recurrent chromosomal rearrangements that produce specific gene fusions. For pathologists, identification of these fusions as well as other characteristic mutational alterations aids in precise subclassification. This review will address known recurrent or tumor-specific genetic events in soft-tissue tumors and discuss the molecular approaches commonly used in clinical practice to identify them. Emphasis is placed on the role of molecular pathology in the management of soft-tissue tumors. Familiarity with these genetic events
    [Show full text]
  • Aggressive Angiomyxoma in Pregnancy: a Rare and Commonly Misdiagnosed Entity Kamal Malukani, Amit V
    Published online: 2020-02-19 Case Report Access this article online Quick Response Code: Aggressive angiomyxoma in pregnancy: A rare and commonly misdiagnosed entity Kamal Malukani, Amit V. Varma, Devashish Choudhary, Shilpi Dosi Website: www.jlponline.org Abstract: DOI: 10.4103/JLP.JLP_179_17 Aggressive angiomyxoma (AAM) is an uncommon mesenchymal tumor that predominantly involves the pelvis and perineum of young females. It is often clinically mistaken for more common superficial lesions such as vaginal cysts, labial cysts, and lipomas. A review of the medical literature reveals very few cases of AAM reported in pregnancy. We describe a rare case of AAM in pregnancy, clinically misdiagnosed as prolapsed cervical fibroid. Key words: Aggressive angiomyxoma, mesenchymal tumors, pregnancy Introduction (G2 P1 L1), married for 5 years, presented with bleeding per vagina for 3 days. She ggressive angiomyxoma (AAM) is also complained of huge mass coming out Aa rare mesenchymal neoplasm of of vagina, difficulty in walking, and pain vulvo‑perineal region and usually found in abdomen and lower back. There was [1] in women of reproductive age group. It no history of fever, weight loss, trauma, is a slow‑growing, low‑grade neoplasm bowel or bladder disturbance, and use of but is locally infiltrative, and relapse any contraceptive. Her menstrual history has been reported in about 30%–40% of and past history were unremarkable. Local cases even after many years of complete examination showed a large pedunculated, resection.[2] Rarely, AAM can metastasize well‑circumscribed, ulcerated mass coming to lungs, peritoneum, and lymph nodes.[3] out of the vagina. Only a few cases of AAM coexistent Ultrasound of abdomen showed with pregnancy are reported in medical bulky anteverted uterus, measuring literature.[4,5] AAM grows to a huge size 9.6 cm × 7.6 cm × 5.4 cm.
    [Show full text]
  • Desterrando El Término Ewing-Like Sarcoma: ¿Qué Entidades Se Cobijaban Bajo Esa Denominación?
    Desterrando el término Ewing-like sarcoma: ¿Qué entidades se cobijaban bajo esa denominación? Sílvia Bagué Servei de Patologia Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona #SEOM20 No disclosures Small round cell sarcomas (SRCS) - Group of malignant neoplasms sharing histological similar features - Mainly in children & young adults - High-grade by definition. Often “translocated-sarcomas” • Ewing sarcoma • “Ewing-like” sarcomas • Desmoplastic SRCT • Alveolar rhabdomyosarcoma • Poorly diff sinovial sarcoma • Mesenchymal chondrosarcoma • High-grade myxoid liposarcoma • Small cell osteosarcoma • Undiff sarcoma with round cell morphology (USRCS) #SEOM203 Ewing sarcoma • Most common round cell sarcoma • 1st - 2nd decade • 85% diaphysis-metaphysis long bones > pelvis, ribs, chest wall (‘Askin’) • 15% extraeskeletal (adults) • Key morphologic features: uniform monotonous round cells, fine chromatin, inconspicious nucleoli, scant clear to pale cytoplasm • Key immunohistochemical stains: strong and diffuse membranous CD99 expression; NKX2+, PAX7+ • Genetics: fusion between EFT genes (FUS, EWSR1) and TAF15 genes and ETS transcription factor family members (Fli-1, ERG, ETV1, ETV4, FEV, E1AF, ZSG) 85-90% t(11;22)(q24;q12) EWSR1- FLI1 fusion gene 5-10 % t(21;22)(q22;q12) EWSR1-ERG fusion gene CD99 FISH EWSR1 #SEOM204 Desmoplastic small round cell tumor Clinical history Boy, 12 y-o. Intraabdominal mass #SEOM205 DSRCT: IHC & genetics Malignant round cell tumor with desmoplastic stroma, poliphenotypic differentiation and translocation
    [Show full text]
  • The 2020 WHO Classification of Soft Tissue Tumours: News and Perspectives
    PATHOLOGICA 2021;113:70-84; DOI: 10.32074/1591-951X-213 Review The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives Marta Sbaraglia1, Elena Bellan1, Angelo P. Dei Tos1,2 1 Department of Pathology, Azienda Ospedale Università Padova, Padova, Italy; 2 Department of Medicine, University of Padua School of Medicine, Padua, Italy Summary Mesenchymal tumours represent one of the most challenging field of diagnostic pathol- ogy and refinement of classification schemes plays a key role in improving the quality of pathologic diagnosis and, as a consequence, of therapeutic options. The recent publica- tion of the new WHO classification of Soft Tissue Tumours and Bone represents a major step toward improved standardization of diagnosis. Importantly, the 2020 WHO classi- fication has been opened to expert clinicians that have further contributed to underline the key value of pathologic diagnosis as a rationale for proper treatment. Several rel- evant advances have been introduced. In the attempt to improve the prediction of clinical behaviour of solitary fibrous tumour, a risk assessment scheme has been implemented. NTRK-rearranged soft tissue tumours are now listed as an “emerging entity” also in con- sideration of the recent therapeutic developments in terms of NTRK inhibition. This deci- sion has been source of a passionate debate regarding the definition of “tumour entity” as well as the consequences of a “pathology agnostic” approach to precision oncology. In consideration of their distinct clinicopathologic features, undifferentiated round cell sarcomas are now kept separate from Ewing sarcoma and subclassified, according to the underlying gene rearrangements, into three main subgroups (CIC, BCLR and not Received: October 14, 2020 ETS fused sarcomas) Importantly, In order to avoid potential confusion, tumour entities Accepted: October 19, 2020 such as gastrointestinal stroma tumours are addressed homogenously across the dif- Published online: November 3, 2020 ferent WHO fascicles.
    [Show full text]
  • Multinucleate Cell Angiohistiocytoma
    To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only by the author(s), editor(s), reviewer(s), Elsevier and typesetter Toppan Best-set. It is not allowed to publish this proof online or in print. This proof copy is the copyright property of the publisher and is confidential until formal publication. These proofs may contain color(colour) figures. Those figures may print black and white in the final printed book if a color(colour) print product has not been planned. The color(colour) figures will appear in color(colour) in all electronic versions of this book. s0060 MULTINUCLEATE CELL ANGIOHISTIOCYTOMA s0065 Definition • Fibroblast-like and histiocyte-like mononuclear cells u0390 p0300 • A distinctive benign dermal proliferation composed • Thickened collagen bundles, frequently hyalinized u0395 of thin-walled capillaries and veins, admixed with • Occasional inflammatory cells, predominantly u0400 scattered multinucleated cells lymphocytes • Hemorrhage absent, no hemosiderin deposition u0405 s0070 Clinical features • Decreased elastic fibers in the dermis can be observed u0410 s0075 Epidemiology • Overlying epidermis normal, but can also be u0415 p0310 • Female predominance (F:M = 3 : 1) hyperplastic u0275 • Middle-aged adult patients • Proliferation restricted to upper and middermis u0420 s0080 Presentation Immunopathology/special stains s0100 p0325 • Slowly growing single or multiple firm, red-brown to • Multinucleated cells display variable CD68 positivity
    [Show full text]
  • Requires Subscription
    DERMATOLOGY PRACTICAL & CONCEPTUAL www.derm101.com An unusual lesion on the nose: microvenular hemangioma A. Tulin Mansur1, Gulsen Tukenmez Demirci2, Eltaf A. Ozbal Koc3, Semsi Yildiz4 1 Dermatology Department, Istanbul Hospital, Baskent University, Istanbul, Turkey 2 Dermatology Department, Acibadem Altunizade Hospital, Acibadem University, Istanbul, Turkey 3 Ear, Nose and Throat Diseases Department, Istanbul Hospital, Baskent University, Istanbul, Turkey 4 Pathology Department, Istanbul Hospital, Baskent University, Istanbul, Turkey Key words: vascular anomaly, hemangioma Citation: Mansur AT, Tukenmez Demirci G, Ozbal Koc EA, Yildiz S. An unusual lesion on the nose: microvenular hemangioma. Dermatol Pract Concept. 2018;8(1):7-11. DOI: https://doi.org/10.5826/dpc.0801a02 Received: April 25, 2017; Accepted: October 6, 2017; Published: January 31, 2018 Copyright: ©2018 Mansur et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: None. Competing interests: The authors have no conflicts of interest to disclose. All authors have contributed significantly to this publication. Corresponding author: Gulsen Tukenmez Demirci, Associate Professor, Dermatology Department, Acibadem Altunizade Hospital, Üsküdar 34662, Istanbul,˙ Turkey. Email: [email protected] ABSTRACT Microvenular hemangioma (MVH) is an acquired, benign type of hemangioma that usually manifests itself as a solitary, slowly growing, red to violaceous, asymptomatic papule, plaque or nodule. It is typically located on the trunk or extremities of young adults. It can be difficult to differentiate MVH from other types of hemangioma and Kaposi sarcoma. Herein we report a case of MVH unusual for its location, age of onset, and morphologic features.
    [Show full text]
  • MR Imaging of Aggressive Angiomyxoma of the Female Pelvis: Case Report
    MR Imaging of Aggressive Angiomyxoma of the Female Pelvis: Case Report Hye Mi Kim1, Ji Eun Pyo2, Nam Hoon Cho2, Nam Kyu Kim3, and Myeong-Jin Kim1 Aggressive angiomyxoma is a rare tumor that predominantly occurs in the female genital tract. Because of its high tendency for local recurrence, preoperative diagnosis is important to ensure wide excision and reduce recurrence risk. But it is often misdiagnosed due to its rarity. We present two cases of aggressive angiomyxoma: a recurrent case that was initially misdiagnosed and a preoperatively diagnosed case. Index words : Myxoma Magnetic resonance (MR) Vulva Female Perineum Case 1 Introduction A 43-year-old woman presented with a non tender mass in the right perirectal area in 1999. Magnetic Aggressive angiomyxoma is a recently characterized resonance (MR) imaging showed a large soft-tissue, 12 benign mesenchymal tumor occurring predominantly ×8×5 cm mass, mainly located at the right perineum in the perineal area, with a strong female extending to the perirectal space. The mass displaced predominance in the 3rd-5th decades of life (1). It has a the adjacent soft tissue and splitted the internal and high propensity for local recurrence, thus preoperative external right levator ani sphincter muscle. It was diagnosis is important for planning surgical isointense to muscle on T1-wighted and hyperintense management (2). But it has been often misdiagnosed on T2-weighted images, with a whirling pattern (Fig. 1). due to its rarity (3). Differential diagnosis included a neurogenic tumor, To our knowledge, the imagings of aggressive myxoid liposarcoma, angiomyolipoma or other soft angiomyxoma have not been reported in Korea.
    [Show full text]
  • Cellular Angiofibroma: a Rare Vulvar Neoplasm Distinct from Aggressive Angiomyxoma Jasvinder Kaur Bhatia*1, R Nangia2
    Case Report Cellular Angiofibroma: A Rare Vulvar Neoplasm Distinct From Aggressive Angiomyxoma Jasvinder Kaur Bhatia*1, R Nangia2 1Department of Pathology, Armed Forces Medical college Pune, India 2SR Adv Pathology, CHCC Lucknow, India Keywords: Cellular Angiofibroma, Vulva, Immunohistochemistry, Aggressive Angiomyxoma. ABSTRACT Cellular angiofibroma (CA) is a rare benign mesenchymal neoplasm of the genital region of both the genders. In women, it arises in late reproductive age and can be cured by complete local excision. It is characterized by a bland spindle cell population and numerous small- to medium-sized vessels with hyalinization. We report a rare case in a postmenopausal woman with a view to highlight the importance of differentiating it from similar more aggressive tumours like aggressive angiomyxoma. A 56 year old woman presented with superficial painless swelling of the vulva and the mass was surgically excised. Histological examination revealed spindle cell proliferation and hyalinised blood vessels in a loosely cellular stroma. Immunohistochemistry revealed positivity for vimentin and CD34 and positivity for ER & PR. *Corresponding author: Dr Jasvinder Kaur Bhatia, Department of Pathology, Armed Forces Medical College, Pune-40, India Phone: +91 - 8552825142 E-mail: [email protected] This work is licensed under the Creative Commons Attribution 4.0 License. Published by Pacific Group of e-Journals (PaGe) C-214 Cellular Angiofibroma Introduction Immunohistochemistry: The tumour cells were positive Cellular Angiofibroma (CA) is a rare benign mesenchymal for vimentin and CD34, ER and PR. (Fig 4, 5, 6, 7) The neoplasm of the genital region of both the genders. It arises tumour was negative for S-100 protein, actin, desmin and in women of late reproductive age [1, 2] and can be cured EMA.
    [Show full text]
  • Conversion of Morphology of ICD-O-2 to ICD-O-3
    NATIONAL INSTITUTES OF HEALTH National Cancer Institute to Neoplasms CONVERSION of NEOPLASMS BY TOPOGRAPHY AND MORPHOLOGY from the INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY, SECOND EDITION to INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY, THIRD EDITION Edited by: Constance Percy, April Fritz and Lynn Ries Cancer Statistics Branch, Division of Cancer Control and Population Sciences Surveillance, Epidemiology and End Results Program National Cancer Institute Effective for cases diagnosed on or after January 1, 2001 TABLE OF CONTENTS Introduction .......................................... 1 Morphology Table ..................................... 7 INTRODUCTION The International Classification of Diseases for Oncology, Third Edition1 (ICD-O-3) was published by the World Health Organization (WHO) in 2000 and is to be used for coding neoplasms diagnosed on or after January 1, 2001 in the United States. This is a complete revision of the Second Edition of the International Classification of Diseases for Oncology2 (ICD-O-2), which was used between 1992 and 2000. The topography section is based on the Neoplasm chapter of the current revision of the International Classification of Diseases (ICD), Tenth Revision, just as the ICD-O-2 topography was. There is no change in this Topography section. The morphology section of ICD-O-3 has been updated to include contemporary terminology. For example, the non-Hodgkin lymphoma section is now based on the World Health Organization Classification of Hematopoietic Neoplasms3. In the process of revising the morphology section, a Field Trial version was published and tested in both the United States and Europe. Epidemiologists, statisticians, and oncologists, as well as cancer registrars, are interested in studying trends in both incidence and mortality.
    [Show full text]
  • UC Davis Dermatology Online Journal
    UC Davis Dermatology Online Journal Title Erythematous asymptomatic nodule on the sole Permalink https://escholarship.org/uc/item/9969k7kp Journal Dermatology Online Journal, 23(10) Authors Paret-Sanz, Cristina del Alcázar-Viladomiu, Elena Pérez-Muñoz, Noelia et al. Publication Date 2017 DOI 10.5070/D32310037003 License https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Volume 23 Number 10 | October 2017 Dermatology Online Journal || Case Presentation DOJ 23 (10): 12 Erythematous asymptomatic nodule on the sole Cristina Paret-Sanz1 MD, Elena del Alcázar-Viladomiu MD, Noelia Pérez-Muñoz2 MD, Ana Iglesias-Plaza1 MD, Montserrat Salleras-Redonnet1 MD PhD Affiliations: 1Department of Dermatology, Hospital Universitari Sagrat Cor, Barcelona, Spain, 2Department of Pathology, Hospital Universitari Sagrat Cor, Barcelona, Spain Corresponding Author: Cristina Paret Sanz MD, Department of Dermatology, Hospital Universitari Sagrat Cor, Carrer de Viladomat, 288, 08029 Barcelona, Spain, Email address: [email protected] Abstract A 75-year-old man presented to the dermatology clinic with an asymptomatic lesion on his right plantar surface. The lesion had progressively grown for two months. Physical examination revealed an erythematous and slightly scaly nodule measuring 10x10 mm. Dermoscopy examination showed central diffuse erythema with small red globules. A punch- biopsy revealed a proliferation of irregularly branched small vessels with collapsed lumen, extending in an infiltrative pattern in the superficial and deep dermis. Although this is a rare location, a diagnosis of microvenular hemangioma was made. Keywords: vascular neoplasm; microvenular hemangioma, hemangioma Introduction Microvenular hemangioma is a rare, benign, acquired vascular tumor, which usually occurs as a solitary slowly enlarging, red, purple, or reddish-blue plaque or nodule of less than 30 mm in diameter.
    [Show full text]